Rats exposed to maternal antibodies against nerve growth factor (NGF) in utero and in milk have been used to investigate the developmental dependency of various substance P-containing neurons on NGF. Substance P and other peptides were measured by radioimmunoassays.
Recently, it has become possible to ascertain the physiological role of nerve growth factor (NGF)5 in UI'UO, both prenatally and postnatahy, by the use of an experimental autoimmune model of NGF deprivation (Gorin and Johnson, 1979; Johnson et al., 1980) . Adult rats or guinea pigs that are immunized with NGF are found to produce anti-NGF antibodies which are transferable in utero to the fetus and in milk to the neonate. This approach facilitates reassessment of the role of NGF in the development of various neurons of the central and peripheral nervous system, a role which heretofore has been defined indirectly by the effect of NGF on embryonic tissues in vitro ' or by the effects of heterologous anti-NGF antiserum in uiuo (Levi-Montalcini and Angeletti, 1968; Levi-Montalcini and Booker, 1960) .
The autoimmune approach has provided additional evidence for the requirement for NGF in the development of immature sympathetic neurons (Gorin and Johnson, 1979) and has provided data which indicate that NGF is required for the maintenance of mature sympathetic neurons (Gorin and Johnson, 1980) . Moreover, anti-NGF antibodies have been shown to have a deleterious effect on the development of sensory neurons (Johnson et al., 1980) . In rats, in utero exposure to anti-NGF antiserum results in a 70% decrease in neuronal cell number in dorsal root ganglia (DRG). The ability of sensory neurons to transport '?-NGF retrogradely (Stoeckel et al., 1975; Gorin and Johnson, 1979 ) is similarly impaired. Sensory neurons are comprised of a variety of cell types (Andres, 1961) . As yet, no neurochemical markers have been studied in association with the lesions in sensory ganglia associated with NGF deprivation in utero. In tissue culture, however, the substance P (SP) content of chick embryo DRG neurons is regulated by NGF (Schwartz and Costa, 1979) . Furthermore, NGF has been shown to affect the development of SP-containing neurons in the sensory ganglia of the newborn animal (Kessler and Black, 1980; Otten et al., 1980) . SP is an undecapeptide which has been postulated to serve as a neurotransmitter both in the central (Otsuka and Konishi, 1975; Henry, 1976) and peripheral nervous system (Katayama et al., 1979; Morita et al., 1980) . In particular, it has been suggested that SP functions as a neurotransmitter in certain primary afferents involved in the transmission of pain (Henry, 1976; Randic and Miletic, 1977) . Immunohistochemistry confirms the presence of this peptide in neuronal perikarya of DRG and in the small diameter C fibers projecting to the skin and spinal cord (Chan-Palay and Palay, 1977a, b; Hokfelt et al., 1977) . SP is released from the spinal cord in vivo by the activation of nociceptive sensory afferents, a release which is inhibited by opiates (Yaksh et al., 1980) . In the experiments reported here, rats exposed to anti-NGF antiserum in utero and in milk have been used to investigate further the effects of NGF deprivation on sensory ganglia. An attempt has been made to correlate previously observed changes in cell number and protein content with a specific biochemical alteration in a subpopulation of DRG neurons containing SP. In addition, the sensitivity of other SP-containing neurons to NGF has been determined and the effects of NGF deprivation on opiate receptors in the spinal cord is reported.
Materials and Methods
Substance P radioimmunoassay Peptide conjugation. SP (Peninsula Laboratories, San Carlos, CA) was coupled to bovine serum albumin (BSA, Sigma Chemical Co., St. Louis, MO) with l-ethyl-3-(3-dimethylaminopropyl)carbodi-imide (ECDI, Sigma) using a molar ratio of peptide:BSA:ECDI of 50:1:560 (Goodfriend et al., 1964) . Conjugation was allowed to proceed at room temperature for 20 hr prior to the removal of unreacted SP by dialysis against saline at 4°C for 48 hr. Efficiency of coupling, as monitored by the inclusion of '""I-TyrH-SP in the reaction mixture, was typically 40%.
Immunization. The BSA conjugate of SP in isotonic saline was emulsified with an equal volume of Freund's complete adjuvant (Calbiochem, La Jolla, CA). Approximately 200 pg of the conjugated peptide were injected intradermally at 30 sites on the shaved back of a New Zealand white rabbit. Booster injections using one-half of the initial dose of the immunogen were given at 3-to 4-week intervals. The rabbit was bled 10 to 14 days following the booster dose. SP antibody obtained by this protocol was usable at a final dilution of 1:20,000 with 30% of the added radiolabeled peptide bound to the antibody in the absence of competing ligand.
Iodination of SP. Tyr'-SP (Peninsula Laboratories, San Carlos, CA) was labeled with 1251 (Amersham Corp., Arlington Heights, IL) using a modification of the procedure of Hunter and Greenwood (1962) . Typically, 2 mCi of Na""1 was reacted with an equimolar amount of TyrH-SP in the presence of 10 pg of chloramine T (Eastman, Rochester, NY) in a total reaction volume of 70 ~1. After 25 set at room temperature, the reaction was terminated by the addition of 100 pg of sodium metabisulfite (Fisher Scientific Co.). All reagents were prepared in 100 mM sodium phosphate buffer, pH 7.4. Unreacted peptide was separated from lz51-Tyr'-SP by gel filtration on Sephadex G-10 (24 x 1.2 cm) eluted with 50 mM trifluoroacetic acid containing 0.1% Triton X-100.
Radioimmunoassay incubation conditions. Test substances or standards (100 ~1)) dissolved in 100 mM sodium phosphate buffer, pH 7.4, containing 10% BSA, were incubated for a minimum of 2 hr at 4°C with 100 ~1 of SP antibody diluted in sodium phosphate buffer, pH 7.4, containing 0.1% BSA. Subsequently, 100 ~1 of 12?-TyrH-SP (5,000 to 7,000 cpm) were added and the incubation continued overnight at 4°C. Antibody-bound SP was separated from free peptide at 4°C by the addition of 1 ml of a charcoal slurry containing 10 mg of charcoal, 1 mg of dextran, and 10 mg of BSA. After centrifugation (4,800 x g, 10 min), the radioactivity bound to the antibody was determined by counting an aliquot of the supernatant. Test substances or standards giving less than 15% or more than 85% inhibition of control binding were excluded from the data analysis. Control binding is defined as the binding of '2"I-Tyra-SP to the antibody in the absence of competing ligand. Cross-reactivity is defined as 100 times the ratio of the IC& (molar concentration required to inhibit 50% of the antibody binding of radiolabeled peptide) of SP to the ICW of the test peptide. All test peptides (Peninsula Laboratories) used in crossreactivity studies were assayed in triplicate at a minimum of six concentrations.
Preparation of tissue extracts. SP, somatostatin, and methionine-enkephalin (Met-enkephalin) were extracted from rat tissues by a modification of the procedure of Chang and Leeman (1970) . Tissues were homogenized in 100:3 (v:v) acetone:1 N HCl and extracted on ice for 2 hr prior to centrifugation at 17,000 x g for 20 min. The resultant supernatant was saved and the pellet was reextracted with 80:20 (v:v) acetone:O.Ol N HCl. After 20 min on ice, samples were centrifuged as above, the supernatant was saved, and the pellet was dissolved in 1 N NaOH for protein determination. The combined supernatants were extracted three times with one-third of their combined volume of petroleum ether. The residual aqueous layer was frozen, lyophilized, and stored at -70°C prior to assay. Recovery experiments using '?-TyrR-SP, 1251-Tyr'-somatostatin (New England Nuclear, Boston, MA), or ["HIMet-enkephalin (New England Nuclear, Boston, MA) indicated an overall efficiency of recovery of 89.5%, 88.5%, or 80.9%, respectively. For assay, tissue extracts were reconstituted in 100 mM sodium phosphate buffer, pH 7.4, containing 10% BSA. The levels of peptides in tissue extracts reported here actually refer to levels of SP-, somatostatin-, or Met-enkephalinlike immunoreactivity.
Nerve growth factor (NGF) was extracted from rat submaxillary glands as previously described (Schwartz and Costa, 1977) .
Radioimmunoassays for somatostatin, Met-enkephalin, and /3-NGF. Immunoassays for somatostatin and Met-enkephalin were performed as described for SP using '251-Tyr'-somatostatin and r3H]Met-enkephalin as radiolabeled ligands, respectively. In the radioimmunoassay for somatostatin, 8.4 pg (or 5.1 fmol) was sufficient to displace 50% of the antibody-bound '251-Tyr'-somatostatin. Antiserum to Met-enkephalin was the generous gift of Dr. James L. Meek (Laboratory of Preclinical Pharmacology, National Institute of Mental Health). Fifty percent displacement of antibody-bound ["HIMet-en-kephalin was attainable with 195 pg (or 340 fmol) of Metenkephalin. The radioimmunoassay for ,&NGF was performed as described previously (Schwartz and Costa, 1977) using mouse P-NGF as standard.
Opioid receptor binding assay Preparation of spinal cord membrane suspensions. A crude membrane fraction from rat spinal cord was prepared by a modification of the procedure of Simon et al. (1973) . Fresh spinal cord was homogenized in 10 ml of cold 50 mM Tris-HCl, pH 7.4, in a glass/glass homogenizer. A portion of the crude homogenate was saved for protein determination and the remainder was centrifuged at 12,000 x g for 20 min at 4°C. The resulting pellet was resuspended in 10 ml of ice cold glass-distilled water for 10 min before centrifuging as above. The final pellet was suspended in 100 mM Tris-HCI, pH 7.4, at a final protein concentration of 2 mg/ml. Membranes were stored at -20°C for 1 to 3 days prior to assay, conditions which control experiments indicate do not alter [3H]etorphine binding.
In some experiments, the membrane preparation procedure was altered to include steps which reputedly facilitate the dissociation of endogenous inhibitors of ligand binding (Simantov et al., 1976) . Membranes were incubated either at 37°C for 15 min in Tris buffer or at 4°C for 60 min in Tris buffer containing 100 mM NaCI. Both procedures were followed by three centrifugations and resuspensions in sodium-free medium. Under the assay conditions used here (see below), neither modification of the membrane preparation procedure altered C3H]etorphine binding and the simplified procedure described above was adopted.
Incubation and assay procedure. Incubations with C3H]etorphine (New England Nuclear, 41.4 Ci/mmol) were conducted at 37'C for 30 min with shaking in 500 ~1 of 100 mM Tris-HCl, pH 7.4. Spinal cord membranes (2 mg of protein/ml) were preincubated for 5 min at 37°C prior to the addition of C3H]etorphine and levorphanol (Hoffman-La Roche, Nutley, NJ). Radioactivity bound to membranes was separated from free drug by rapid filtration through Whatman GF/C glass fiber filters. Filters were washed three times with 4 ml of ice cold 100 mu Tris-HCl, pH 7. Animal treatment Adult female Sprague-Dawley rats were immunized with mouse 2.5 S NGF (Bocchini and Angeletti, 1969) as previously described (Gorin and Johnson, 1979) . Such rats have been shown to produce antibodies which crossreact with rat NGF. Females selected as breeders in experiments reported here had been shown previously to produce severely affected litters as judged by the size of the sympathetic ganglia and the tyrosine hydroxylase activity in the superior cervical ganglia of the offspring at birth and by a marked decrease in the ability of littermates to transport '251-NGF retrogradely to the sensory ganglia. The offspring used here were exposed to anti-NGF antibody in utero and in milk. Controls were age-matched offspring of mothers not immunized with NGF prior to or during pregnancy.
All rats were killed at maturity by decapitation. Tissues of interest were removed immediately, frozen on dry ice, and stored at -70% prior to extraction. In those instances in which both neuropeptide levels and opioid receptor binding were measured in the spinal cord, individual spinal cords were removed, placed on ice, and sliced into 2-mm cross-sectional slices. Alternate slices were pooled and saved either for immunoassay or radioreceptor assay.
Rat brains were sliced into 400~pm sections in a cryostat at -10°C. Discrete nuclei were removed from frozen sections using a stainless steel dissecting needle as described by Palkovits (1973) . Punches were stored at -70°C prior to extraction.
Protein determination
Protein concentrations were determined by the method of Lowry et al. (1951) using BSA as standard.
Results
Substance P radioimmunoassay characteristics. The antiserum raised to a BSA conjugate of SP allows measurement of SP over the concentration range of 25 to 350 PM. Half-maximal displacement of '251-Tyr*-substance P is attainable with 108 PM nonradioactive SP or a concentration of 140 pg/ml. Specificity studies with fragments of SP are summarized in Table I . The results indicate that the primary antigenic determinant is localized in the NHz-terminal portion of SP with amino acid residues 4 and 5 most directly implicated in antibody recognition. The COOH-terminal fragment, SP-(6-11), is ineffective in competing for antibody binding even at concentrations 5,000 times higher than the I&O for SP. SP biological activity has been shown to be connected specifically to the COOH-terminal hexapeptide (Bury and Mashford, 1976) . Hence, the antibody recognition site differs from that of the SP receptor. Effect of NGF deprivation on neuropeptide levels in DRG, skin, and spinal cord. Exposure of rats to NGF antibody in utero and in milk dramatically alters the SP content of sensory ganglia (Table II) . Treated rats killed in maturity showed a 56% depletion of SP in DRG compared with age-matched controls. SP levels in the target tissues innervated by these neurons also were reduced significantly in treated animals. Exposure to NGF antibodies reduced SP levels of the skin of the rat hind paw by 57%, a depletion of comparable magnitude to that observed in DRG. Spinal cord levels of SP were reduced from 1.52 ng/mg of protein to 0.95 ng/mg or a total reduction of 37.5%. The smaller proportional decrease in spinal cord reflects the diverse origin of SPcontaining neurons contributing to that pool. While a substantial portion of spinal cord SP is localized in terminals of primary afferents, a significant contribution also arises from the descending raphe-spinal pathway in which SP appears to coexist with serotonin (Chan-Palay et al., 1978; Hokfelt et al., 1978) .
In addition to SP, somatostatin has been reported to be present in the small diameter cells of sensory ganglia which project to the dorsal horn of the spinal cord (Hokfelt et al., 1975) . No effect of NGF deprivation was noted on levels of somatostatin-like immunoreactivity in either DRG or spinal cord when the data were expressed per milligram of protein (Table II) . There was a 30% decrease (not statistically significant) in ganglion levels when the data were expressed as picograms per ganglia, in agreement with preliminary results from guinea pigs exposed to anti-NGF antiserum (J. P. Schwartz, M. Ross, S. Lofstrandh, P. D. Gorin, and E. M. Johnson, unpublished results). It is possible that the measurement of somatostatin in whole spinal cord obscured a significant change in the levels in the dorsal horn since a considerable portion of somatostatin in the spinal cord is associated with intrinsic neurons (Burnweit and Forssmann, 1979) .
Effect of exposure to NGF antibodies on opiate receptor binding in rat spinal cord. A close correlation between SP and the opioid peptide, enkephalin, has been suggested in dorsal horn (Hokfelt et al., 1977) . A number of lines of evidence indicate that opiate receptors may be located presynaptically on SP primary afferents (La Motte et al., 1976; Jessell and Iversen, 1977; Hiller et al., 1978; Mudge et al., 1979; Fields et al., 1980) . Table III (10) 0.67 f 0.07 (9) Globus pallidus 0.95 f 0.16 (10) 0.78 f 0.08 (9) Habenula 0.57 f 0.06 (10) stantia nigra, dorsal raphe, and intrapeduncular nucleus. However, no difference in SP levels was noted between control and treated animals in any of the nine brain regions studied.
Dependence of SP levels in selectedperipheral tissues on NGF. SP innervation of the adrenal (Linnoila et al., 1980) and ileum (Schultzberg et al., 1980; Costa et al., 1981) has been demonstrated by immunofluorescence. In addition, SP has been localized in amacrine cells of the retina (Karten and Brecha, 1980) by immunohistochemistry and in the submaxillary gland by radioimmunoassay (Robinson et al., 1980) . When the SP content of these tissues was compared in treated and control rats, levels in retina, submaxillary gland, and ileum were unaffected by the presence of anti-NGF antibody during development (Table V) . Interestingly, the levels of NGF in submaxillary glands, as determined by a specific radioimmunoassay, were also unchanged (control (n = 5), 3.44 + 0.33; treated (n = 5), 3.30 f 0.35 ng/mg of protein).
However, the SP content of adrenal glands was decreased significantly in treated animals versus controls.
Discussion
A physiological role for NGF in the developing nervous system has been established most convincingly by monitoring the effects of in vivo NGF deprivation. Such deprivation currently can be achieved through the autoimmune approach described by Gorin and Johnson (1979) ; other possible approaches to NGF depletion are hampered by the lack of a specific NGF antagonist and by the lack of definitive information on the tissue sources of NGF. The validity of the autoimmune approach has been strengthened by recent evidence that the effects of anti-NGF antibodies arise directly from the neutralization of endogenous NGF rather than from a complementmediated cytolysis (Ennis et al., 1979; Goedert et al., 1980) .
The autoimmune approach has provided strong evidence for a requisite function for NGF in sensory neuron development (Gorin and Johnson, 1979; Johnson et al., 1980) . In utero exposure to anti-NGF antibody results in a 70% depletion in cell number in the sensory ganglia in rats. The experiments reported here suggest that part of that depletion can be attributed to the loss of SP-containing neurons. SP is contained within small diameter cells of the sensory ganglia (Chan-Palay and Palay, 1977a, b; Hokfelt et al., 1977) , the cell population which size frequency histograms indicate is affected most severely by anti-NGF antibody (Johnson et al., 1980) . It is noteworthy, however, that the depletion of SP observed in ganglia (and in the target tissue skin) is incomplete, with 43 to 44% of the control levels of SP persisting in treated rats. An incomplete destruction of SP neurons in the rat is inferred from the fact that the rats appear normally responsive to painful stimuli. This is in contrast to guinea pigs born to anti-NGF producing mothers which are insensitive to painful stimuli (e.g., capsaicin). As expected, preliminary experiments indicate much greater decreases in SP in DRG and spinal cord in these animals (J. P. Schwartz, M. Ross, S. Lofstrandh, P. D. Gorin, and E. M. Johnson, unpublished results). This incomplete destruction of SP neurons may be indicative of an insufficient titer of NGF antibody or of insufficient access of maternal antibodies to the fetus during critical stages of development.
Alternatively, there may exist more than one population of SP neurons in DRG which subserve different sensory functions and which possess different sensitivities to NGF. Somatostatin levels in DRG, expressed per milligram of protein, were unaffected by prenatal and postnatal exposure to anti-NGF antiserum in rats. However, preliminary results show a significant change in somatostatin levels in affected guinea pig DRG, and again, the difference may reflect the greater sensitivity of the guinea pigs to exposure to anti-NGF.
Direct evidence for the sensitivity of somatostatin neurons to NGF comes from tissue culture work (Mudge, 1979) . However, differences in the growth factor responsiveness of somatostatinand SP-containing neurons have been noted previously. In primary culture, ganglionic non-neuronal cells, presumably through the release of a trophic factor other than NGF (Lindsay, 1980) , have been shown to increase the level of somatostatin relative to SP (Mudge, 1979) . Central SP neurons were unaffected by exposure to anti-NGF antiserum in utero and in milk. Such refractoriness of central neurons to NGF is in agreement with previous observations on noradrenergic neurons in culture. While peripheral sympathetic neurons are exquis-itely sensitive to NGF both prenatally and postnatally, embryonic adrenergic neurons from the locus coeruleus or cortex were not responsive to NGF (or anti-NGF antibody) in cell culture (Olson et al., 1979) . However, it is again possible that the failure to detect an effect of anti-NGF antibodies on central SP neurons is the result of inadequate in utero exposure. Confirmation of this and other negative findings reported here should be sought in guinea pigs, a species in which larger quantities of maternal antibodies are transferred prenatally (Brambell, 1970) . The decreased level of immunoreactive SP observed in adrenal glands is noteworthy. SP innervation of the adrenal has been established by immunohistochemistry (Linnoila et al., 1980) . A physiological role for this peptide in inhibiting the acetylcholine-stimulated release of catecholamines from chromaffin cells has been suggested (Livett et al., 1979) . However, little is known of these neurons and their cell bodies have yet to be identified.
No decrease in opiate receptor density was detected in rats exposed to anti-NGF antibody during development despite a substantial reduction in SP levels in spinal cord. Since the decreased levels of SP presumably reflect cell death (Johnson et al., 1980) , this result contrasts markedly with observations suggesting that opiate receptors are located presynaptically on SP-containing primary afferents. The presynaptic localization of opiate receptors on sensory terminals has been inferred from the loss of spinal cord opiate receptors observed after dorsal rhizotomy (La Motte et al., 1976; Jessell et al., 1979) and from the depletion of spinal cord opiate receptors noted after treatment of newborn rats with capsaicin (Gamse et al., 1979; Nagy et al., 1980) . The ability of opiates to inhibit stimulated SP release in spinal cord in viva (Yaksh et al., 1980 ) lends support to a presynaptic localization of opiate receptors as do in vitro experiments which show an inhibitory action of opiates on SP release from rat trigeminal nucleus (Jessell and Iversen, 1977) and DRG neurons (Mudge et al., 1979) .
While the negative findings reported here apparently contradict the presynaptic localization of opiate receptors on SP sensory terminals, it is possible that the use of whole spinal cord in the determination of opiate receptor number obscured a significant difference in a relatively small population of receptors localized on primary afferents (Herkenham and Pert, 1980) . Additional experiments using tissue derived only from dorsal horn may clarify this issue. It is noteworthy, however, that electron microscopic studies on the synaptic relationships of SP axons in spinal cord have failed to produce morphological support for the presynaptic localization of opiate receptors on SP primary afferents (Ralston and Ralston, 1979; Barber et al., 1979) . Immunohistochemical techniques show SP primary afferents largely in lamina I of the dorsal horn. Primary afferents in that region do not appear to participate in axoaxonal contact and, hence, are unlikely to be subject to presynaptic inhibition. The electron microscopic examination of Met-enkephalincontaining neurons in the spinal cord also has failed to reveal a direct interaction between primary afferents and enkephalinergic neurons (Hunt et al., 1980) .
The autoimmune model has provided strong evidence that, during early development, substance P-containing sensory neurons are dependent on NGF or a closely related cross-reacting substance. Subsequent experiments with this model can be expected to define more precisely the critical stage during which NGF is required for survival of these neurons. A re-examination of the role of NGF in the postnatal development of SP-containing sensory neurons (Kessler and Black, 1980,198l; Otten et al., 1980) and an evaluation of the importance of NGF in the maintenance of mature sensory neurons should be undertaken also. Finally, the ability of anti-NGF antibodies to impair the development of SP-containing sensory neurons suggests that the autoimmune model will provide an important new approach to investigating the role of SP in pain perception. 
